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Table 1. Clinical characteristics of 3 patients with sickle cell disease.
Case 1 (F/26) Case 2 (M/33) Case 3 (F/26)
Diagnosis Sickle cell anemia (HbSS) Sickle cell anemia (HbSS) Sickle beta thalassemia (HbS0)
Prior treatment
     Hydroxyurea Continuous Previous Continuous
     RBC transfusion or RCE RCE, once RCE, regularly RBC transfusion, frequently
Organomegaly No No No
History of SCD-related 
complications
Vaso-occlusive pain Vaso-occlusive pain Avascular necrosis
Acute chest syndrome Vaso-occlusive pain
Secondary hemochromatosis
Current symptom Intermittent bone pain Intermittent lower back pain Pain of lower back and both knee
Laboratory data on admission
     Hb (g/dL, reference range)   10.6 (12.0–16.0)     9.7 (13.0–18.0)     9.0 (12.0–16.0)
     Hct (%, reference range)   29.4 (34.0–49.0)   27.7 (40.0–54.0)   27.3 (34.0–49.0)
     LDH (U/L, reference range)    454 (250–450) 1,275 (250–450)    504 (250–450)
     Ferritin (ng/mL, reference range) 185.5 (13–150)   77.6 (30–400) 5,665 (13–150)
     HbS (%) 70.8 64.5 89.3
     Genotype of SCD c.20A＞T (p.Glu7Val), 
homozygosity
c.20A＞T (p.Glu7Val), 
homozygosity
c.20A＞T (p.Glu7Val), 
heterozygosity
c.92+1G＞A, heterozygosity
Hematopoietic stem cell transplantation
     Donor source HLA matched sibling HLA matched sibling HLA matched sibling
     HSCT type Nonmyeloablative allogeneica) Nonmyeloablative allogeneica) Nonmyeloablative allogeneica)
     Day of HSCT after last RCE 9th day 8th day 9th day
a)Nonmyeloablative allogeneic HSCTs were performed according to reference [4].
Abbreviations: Hb, hemoglobin; HCST, hematopoietic stem cell transplantation; Hct, hematocrit; HLA, human leukocyte antigen; LDH, lactate
dehydrogenase; RBC, red blood cell; SCD, sickle cell disease; RCE, red cell exchange.
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TO THE EDITOR: Sickle cell disease (SCD), a group of in-
herited red cell disorders, results from the presence of at 
least one abnormal sickle hemoglobin (HbS) allele. Vaso-oc-
clusive complications in multiple organs and tissues, and 
hemolytic anemia are the main features of SCD [1]. 
Management of acute and chronic complications of SCD 
includes red blood cell (RBC) transfusion and red cell ex-
change (RCE) by manual or automated methods [2]. Acute 
RCE is used to treat severe or life-threatening complications 
of SCD including acute stroke, acute chest syndrome, multi-
organ failure, severe intrahepatic cholestasis, and priapism. 
Chronic RCE is used to prevent either new or recurrent 
adverse events or progression of preexisting organ dysfunc-
tion, and this treatment is particularly indicated for stroke 
prophylaxis with prevention of iron overload, as well as 
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Table 2. Profiles of red cell exchange performed on 3 patients with sickle cell disease.
Case 1 (F/26) Case 2 (M/33) Case 3 (F/26)
ABO/RhD type B+ B+ O+
Rh subtype Not tested CcEe Ccee
Antibody screening test
   Before RCE Negative Negative Positive (anti-E+anti-Kpa)
   After RCE Negative Negative Negative
Parameters for RCE 
   Body weight (kg) 66.0 90.5 49.0
   Height (cm) 162.0 182.7 153.3
   TBV (mL) 3,880 5,754 3,086
   Target FCR (%) 35 30–35 30
   Initial Hct (%) 29.4 29.6 25.7
   Target Hct (%) 30 30 30
   Hct of packed RBC component (%) 70 70 70
   Inlet/outlet balance (%) 100 100 100
   Estimated replacement volume (mL) 1,702 2,685 1,441
   Used packed RBCs (units per each RCE) 7/7/8 11/11 6/6
   Total number of RCE before HSCT 3 2 2 
   Processing time (hr) 2 2.5–3 2.5
   Frequency Every other day Every other day Every day
Abbreviations: FCR, fraction of cells remaining; Hct, hematocrit; HSCT, hematopoietic stem cell transplantation; RBC, red blood cell; RCE, red 
cell exchange; TBV, total blood volume. 
for vaso-occlusive pain, pulmonary hypertension, and 
end-stage renal disease [2, 3]. RCE is also performed as 
part of the preparative regimen for nonmyeloablative alloge-
neic hematopoietic stem cell transplantation (HSCT) [4]. 
To the best of our knowledge, there are no reports on Korean 
patients with SCD; however, the number of international 
patients visiting Korean hospitals has increased recently, 
and clinicians should be prepared to treat rare diseases like 
SCD. Therefore, we report our experiences with successful 
RCE in three Emirati patients with SCD using an apheresis 
instrument, Spectra Optia (version 7.0, TerumoBCT, 
Lakewood, CO, USA), prior to allogeneic HSCT. In all 3 
cases, RCE was performed for prophylactic purposes prior 
to HSCT.
Case 1
A 26-year-old Emirati woman diagnosed with sickle cell 
anemia (SCA) in the United Arab Emirates (UAE) was admit-
ted for allogeneic HSCT. According to her medical records 
from the UAE, she had a history of frequent admissions 
owing to sickle cell crisis, and had undergone a single RCE 
procedure in her country (Table 1). Her physical examina-
tion and laboratory data on admission are shown in Table 
1. Her blood type was B+. The HbS level estimated by 
Hb electrophoresis (EP) was 70.8% of total Hb. HBB gene 
sequencing showed homozygosity of a known missense mu-
tation (c.20A＞T, p.Glu7Val) corresponding to sickle cell 
anemia (HbSS) [5]. She did not receive RBC transfusion 
prior to RCE during her time at our hospital. Three auto-
mated RCE procedures were performed every other day. 
We calculated the total blood volume of the patient using 
the her gender, weight, and height (by Nadler’s method) 
and estimated the patient’s red cell volume using total blood 
volume and each pre-exchange hematocrit (Hct). The target 
FCR (%, fraction of cells remaining=HbS after exchange 
×100/HbS before exchange) at the end of the procedure 
(35%), desired final Hct (30±3%), Hct of the replacement 
RBC units (70%), and inlet/outlet fluid balance (100%) were 
used to determine the replacement volume (RV), using the 
built-in formulae on our apheresis instruments. RV was 
divided by 250 mL to decide the number of packed RBC 
units (7, 7, and 8 units, respectively). All RBC components 
were ABO-identical (B+) and leukocyte-filtered. Therapeutic 
apheresis including RCE requires excellent vascular access 
to achieve adequate flow rates. Peripheral access is preferred 
and generally requires at least a 17-gauge needle for blood 
withdrawal and at least an 18-gauge catheter for return. 
Patients without adequate peripheral veins may require 
placement of a central vascular catheter [6]. In this case, 
a central catheter was used for vascular access because the 
patient’s peripheral veins were not adequate. Inlet blood 
flow rate was between 30 and 35 mL/min and ACD-A anti-
coagulant was infused at a ratio of 1:13–1:15 (Table 2). The 
blood flow rate was selected to achieve a procedure length 
of 2–3 hours, a generally accepted period of time. In general, 
the higher the anticoagulation ratio (AC ratio) (＞1:15), 
the less citrate anticoagulant is present in the circuit. A 
higher AC ratio favors the development of platelet clumping 
and interface instability. The lower the AC ratio (＜1:10), 
the greater the concentration of anticoagulant delivered 
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Fig. 1. Change of hemoglobin S (green bars) and Hct (red lines) levels 
of 3 SCD cases according to red cell exchange (black arrows).
Abbereviations: HbS, hemoglobin S; Hct, hematocrit; SCD, sickle cell 
disease; RCE, red cell exchange.
to the patient, which can increase symptoms of citrate tox-
icity [7]. Our patient tolerated the treatment well, and expe-
rienced no adverse reactions during any procedure. No irreg-
ular antibodies to RBCs were detected before or after RCEs. 
All Hct levels after each RCE were within the target Hct 
range (28.8%, 31.0%, and 27.7%, respectively); HbS level 
was 3.5% on the day after the last RCE (Fig. 1). 
Nonmyeloablative allogeneic HSCT [4] was performed nine 
days after last RCE, and level of HbS was 11.6% on the 
morning of the day of HSCT procedure. 
Case 2 
A 33-year-old Emirati man diagnosed with SCA in the 
UAE was admitted for allogeneic HSCT. According to his 
medical records from the UAE, he experienced frequent 
sickling crisis rashes with acute chest syndrome (Table 1), 
was admitted with painful crises and had undergone regular 
RCEs (Table 1). His physical examination and laboratory 
data on admission are shown in Table 1. His blood type 
was B+. HbS level was 64.5% and HBB gene mutation analy-
sis demonstrated a homozygotic missense mutation, c.20A＞
T (p.Glu7Val). He did not receive RBC transfusion prior 
to RCE at our hospital. RCEs were performed twice before 
HSCT, every other day. The parameter settings for estimat-
ing RV were nearly the same as those in the previous case. 
Rh antigen (D, C, c, E and e)-matched packed RBCs were 
selected for replacement not in the first RCE but in the 
second RCE. Peripheral lines were used for vascular access 
in the first exchange, and a central line was used for the 
second procedure. Inlet blood flow rate was between 40 
and 45 mL/min, and ACD-A anticoagulant was infused at 
a ratio of 1:13–1:15 (Table 2). Urticaria appeared during 
first procedure, but quickly resolved following anti-hista-
mine medication administration. No irregular antibodies 
to RBCs were detected before or after the RCE procedures. 
All Hct levels after each RCE were within target Hct range 
(28.0% and 28.4%, respectively); HbS level was 3.8% on 
the day after the final RCE (Fig. 1). Nonmyeloablative alloge-
neic HSCT was performed eight days after the last RCE, 
but the HbS level was not tested immediately before HSCT.
Case 3 
A 26-year-old Emirati woman diagnosed with SCD in 
the UAE was admitted for allogeneic HSCT. According to 
her medical records from the UAE, she had a history of 
SCD-related complications including recurrent pain crisis 
and avascular necrosis of the left hip (Table 1). Her physical 
examination and laboratory data on admission are shown 
in Table 1. Her blood type was O+. HbS level was 89.3% 
of total Hb. In HBB gene mutation analysis, heterozygosity 
of beta-globin gene mutations was found as a known mis-
sense mutation, c.20A＞T (p.Glu7Val) corresponding to 
sickle cell anemia and a known splicing site mutation in 
intron 1 (c.92+1G＞A) corresponding to beta-thalassemia 
[8]. The final diagnosis was sickle-beta-thalassemia (HbS0) 
with known mutations in the HBB gene [8]. She did not 
receive RBC transfusion prior to RCE during her stay in 
our hospital. RCEs were performed twice before HSCT on 
two consecutive days. RV was estimated using the same 
method as that used with the previous patient. Six units 
of ABO-identical (O+), leukocyte-filtered, and Rh antigen 
(D, C, c, E and e)-matched packed RBCs were selected 
for replacement. Vascular access required both peripheral 
(return) and central (access) lines. Inlet blood flow rate 
was 25 mL/min, and ACD-A anticoagulant was infused at 
a ratio of 1:13–1:15 (Table 2). All procedures were tolerated. 
Alloantibodies such as anti-Kpa and anti-E (only detected 
with enzyme-treated reagent cells) were weakly detected 
prior to RCE, but no new onset alloantibodies were detected 
after the procedures. All Hct levels after each RCE were 
within the target Hct range (32.7% and 31.5%, respectively). 
HbS levels were 4.3% on the day after the final RCE (Fig. 
1). Nonmyeloablative allogeneic HSCT was performed 9 
days after the last RCE, but the HbS level was not estimated 
immediately prior to HSCT. 
RBC transfusion and RCE are among the main therapeutic 
modalities for both acute and chronic complications related 
to SCD, although allogeneic HSCT is considered a potentially 
curative therapy for SCD patients [9]. Although simple RBC 
transfusion is easy to perform, automated RCE is shown 
to be efficient in reducing sickle cells without complications 
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such as increasing a patient’s blood volume and viscosity, 
and causing iron overload [1, 2]. According to the American 
Society for Apheresis (ASFA) [2], general guidelines for 
RCE in patients with SCD are end Hct of 30±3% to avoid 
hyperviscosity and HbS of 30% (or HbS+HbC of 30%). In 
adult patients with SCD, in preparation for non-
myeloablative allogeneic HSCT, it is recommended that RCE 
be performed to reduce HbS levels to 30% or less [4, 9]. 
In the present study, final HbS levels in all 3 patients were 
less than 10% after 2 or 3 RCE procedures, demonstrating 
successful achievement of the target goal.
Most patients with SCD require chronic RBC transfusion, 
and thus are at high risk of alloimmunization. In patients 
with SCD, alloantibodies to the Rhesus system and to the 
K antigen account for over two-thirds of the RBC antibodies 
encountered in all populations studied. Alloantibodies to 
antigens in the Kidd, Duffy, Lewis, and MNS systems are 
also frequently formed in these patients. Anti-Lewis anti-
bodies are usually clinically insignificant; however, the re-
maining antibodies formed by patients with SCD can poten-
tially lead to hemolytic transfusion reactions and delays 
in finding compatible RBC units [10]. Therefore, ABO, full 
Rhesus (D, C/c, E/e), and Kell antigen-matched blood should 
be recommended to prevent RBC alloimmunization [11]. 
The RBC unit, which is HbS negative, leukocyte-reduced, 
and antigen-matched (C, c, E, e, K), is presented because 
long-term blood donor exposure can potentially increase 
the risk of infectious transmission and RBC alloimmuniza-
tion [2]. We used ABO-identical and leukocyte-filtered RBC 
units for replacement in all 3 cases. RBC units with full 
Rhesus antigen matching (with the exception of the K anti-
gen) were used in the second RCE in Case 2 and all RCEs 
in Case 3. The Rhesus phenotypes of RBC units were pro-
vided by blood centers. Because the prevalence of the K 
antigen is extremely low in the Korean population [12], 
selection of replacement red cells without K antigen match-
ing is not important. Our patients showed no evidence of 
new-onset RBC alloantibodies, and all successfully under-
went HSCT. In Korea, the medical benefits of phenotyping 
of Rhesus systems (C/c and E/e) and other blood groups 
including Kidd and Duffy have limited application. The 
Korean Health Insurance Review and Assessment Service 
provides medical care benefits only for phenotyping hemo-
lytic anemia patients with already formed alloantibodies 
and for phenotyping RBC units to find compatible units 
for these patients. This narrow extent of medical care bene-
fits cannot cover phenotyping for prevention of RBC 
alloimmunization. Although Rhesus phenotypes (C/c and 
E/e) of RBC components were provided by blood centers 
including the Korean Red Cross and Hanmaum Blood 
Center, they recommend that the Rhesus phenotypes be 
confirmed in clinical laboratories when RBC units are issued 
for Rhesus-compatible transfusions. It has been reported 
that exact matching of RBC antigens including ABO, Rh, 
Kell, Kidd, and Duffy for transfusions in patients with SCD 
reduces the extent and rate of alloimmunization, providing 
safer transfusions in a timely fashion, and should be consid-
ered whenever such patients are transfused [13]. Therefore, 
expanding criteria for blood group phenotyping is necessary 
to prevent RBC alloimmunization in patients likely to re-
ceive chronic transfusions, including patients with SCD. 
To our knowledge, there are no reported cases of SCD 
in the Korean population, and there is only one case report 
of HbS0 thalassemia patient from Tunisia receiving prophy-
lactic RCE in Korea before traveling back [14]. Unlike in 
the previous report, we used RBC components with full 
Rhesus antigen-matching, which was found to be helpful 
in preventing RBC alloimmunization. In addition, all RCEs 
were performed as part of a preparative protocol for non-
myeloablative allogeneic HSCT in patients with SCD. 
Therefore, this report will be helpful as more foreign patients 
come to Korea to undergo HSCT for the same reasons. In 
2016, more than 2 million foreign residents including foreign 
workers, students, and intermarriage immigrants were living 
in Korea, constituting about 3.96% of the total population 
[15]. As the number of foreigners increase annually, the 
need for understanding and managing a variety of diseases 
including SCD also increases. In this study, we report the 
cases of three Emirati patients with SCD who received suc-
cessful RCE using the Spectra Optia system (TerumoBCT) 
for reduction of HbS prior to nonmyeloablative allogeneic 
HSCT. Our experiences demonstrate that automated RCE 
is an effective and safe therapeutic modality for rapid reduc-
tion of pathologic HbS in SCD patients over a short period.
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Epstein-Barr virus-positive 
mucocutaneous ulcer colliding with 
extranodal marginal zone lymphoma 
of mucosa-associated lymphoid tissue 
(malt lymphoma) that developed in 
the palatine tonsils of an 
immunocompetent patient after 
gastric lymphoma relapse
TO THE EDITOR: Epstein-Barr virus (EBV)-positive muco-
cutaneous ulcer (MCU) is a recently documented condition 
that occurs in association with various forms of im-
munosuppression representing a unique, indolent form of 
EBV-driven B-cell lymphoproliferative disorder. It charac-
teristically presents as isolated, well-delineated ulcers that 
respond well to conservative therapeutic intervention. It 
is usually located in the oropharyngeal area. Extranodal 
marginal zone lymphoma of mucosa-associated lymphoid 
tissue (MALT lymphoma), a low-grade B-cell lymphoma, 
can present with tonsillar enlargement in the oropharyngeal 
area. Here, we report a case of EBV-positive MCU that 
collided with MALT lymphoma in the palatine tonsils of 
an immunocompetent 49-year-old man with a history of 
gastric MALT lymphoma in complete remission. To our 
knowledge, a collision case of EBV-positive MCU and a 
palatine tonsillar MALT lymphoma relapse of gastric lym-
phoma has not yet been described.
Epstein-Barr virus (EBV)-positive mucocutaneous ulcer 
(MCU) is a newly documented condition occurring in the 
elderly or iatrogenically immunocompromised patients as 
published in the WHO classification of tumors of hema-
topoietic and lymphoid tissues in 2017 [1]. Lesions in the 
oral cavity, gastrointestinal tract, and skin have been 
described. They present as isolated, well-delineated ulcers 
that respond well to conservative therapeutic intervention 
despite large and atypical EBV-positive B-cell infiltration. 
Due to their indolent clinical behavior and excellent 
long-term prognosis, an understanding of the clinical and 
histomorphologic features should help to distinguish be-
tween EBV-positive MCU from ulcerations in the oral cavity 
caused by other high-grade lymphomas.
As one of the B-cell neoplasms showing indolent clinical 
course, extranodal marginal zone lymphoma of muco-
sa-associated lymphoid tissue (MALT lymphoma) is well 
known and can be localized along the aerodigestive tract. 
Histologically, neoplastic marginal zone B-cells are clustered 
throughout the mucosal tissues [2]. In the oral cavity, they 
tend to present as a protruding mass with chronic in-
flammatory processes such as sialadenitis and Sjogren’s syn-
drome [3]. Here, we report a case of EBV-positive MCU 
in the palatine tonsils arising in the setting of MALT lympho-
